Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.41 |
| ▸ | GRM5 | P41594 | 7/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | LIPC | P11150 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28543598 | 0.92 | NAMPT (0.52) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL25415012 | 0.88 | NAMPT (0.48) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL24265983 | 0.87 | NAMPT (0.47) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL22725452 | 0.87 | NAMPT (0.48) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL5824291 | 0.86 | NAMPT (0.54) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL22725409 | 0.85 | CDK7 (0.48) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL31129855 | 0.85 | NAMPT (0.51) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL24794715 | 0.85 | NAMPT (0.51) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL23541190 | 0.84 | NAMPT (0.51) | NAMPTCDK7CDK13CDK12PDK4 | |
| SCHEMBL3985355 | 0.84 | NAMPT (0.50) | NAMPTCDK7CDK13CDK12PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| CN-1199954-C | Benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2005-05-04 | — | — | CN | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| CN-1379764-A | Benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | NAMPT 4561/4885CDK7 2508/4885CDK13 2696/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | NAMPT 4258/4885CDK7 1996/4885CDK13 1985/4885 |
| US-20060148791-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | NAMPT 4258/4885CDK7 1996/4885CDK13 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.